R
RareCyte
Life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood
About RareCyte
RareCyte operates in the precision medicine market, providing advanced solutions for spatial biology and liquid biopsy. The company serves researchers, translational medicine professionals, and clinical leaders by offering highly multiplexed fluorescent imaging systems, reagents, and contract services. These tools enable the detailed analysis of cell and tissue samples, helping to unlock spatial context for key biomarkers and develop therapeutics and companion diagnostics. RareCyte's business model revolves around selling its proprietary imaging systems and consumables, as well as offering custom assay development services. Revenue is generated through product sales and service contracts. The company's innovative technology, such as the AccuCyte Sample Preparation System, simplifies and standardizes the preparation of blood samples for analysis, enhancing the accuracy and reproducibility of results. RareCyte's solutions are pivotal in advancing research and diagnostics, particularly in understanding complex tumor microenvironments and other critical areas of biomedical research.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Seattle, United States
- Employees
- 61
- Open positions
- 3
- Dealroom signal
- 35.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Health Diagnostics, Biotech and Pharma, Hard Tech, medical testing, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jun 2024 | $20M | $120M | 5AM Ventures · Agilent · Ron Seubert · Sheatree Capital | ↗ |
| GRANTOther financing | Nov 2022 | $0 | — | Gastro-Intestinal Research Foundation | ↗ |
Growth signals
Latest recorded traffic for RareCyte is 2.4K monthly website visits, down 65.2% over the last three months. RareCyte's team declined 1.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Gastro-Intestinal Research Foundation
Series B and later11 investors entered at this stage
Telegraph Hill Partners
5AM Ventures
HealthQuest Capital
Arboretum Ventures
F-Prime
Agilent
Logos Capital- RSRon Seubert
The Forest Road Company- SCSheatree Capital
- GKGKCC
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about RareCyte on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RareCyte’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.